Mannkind Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 13, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Mannkind in Mar 31 2026 quarter, has decreased to 28 days, compared to 29 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 69 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 686, from overall ranking in the fourth quarter 2025 at 787.

What is Receivable Turnover Ratio?
What is Mannkind Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MNKD Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-2.64 %	225.03 %	-4.4 %	16.26 %	45.14 %
Y / Y Revenue Change	15.08 %	45.82 %	17.2 %	5.72 %	18.25 %
Receivable Turnover Ratio (TTM)	13	12.49	14.73	14.03	14.48
MNKD's Total Ranking	# 686	# 787	# 1366	# 1271	# 707
Accounts Receivable average collection period days	28	29	25	26	25
Seq. Receivable Change	-26.66 %	120.72 %	-35.96 %	-6.08 %	144.83 %
Seq. Revenue Change	-19.46 %	36.31 %	7.32 %	-2.33 %	2.06 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 29
Healthcare Sector	# 70
Overall Market	# 686

Receivable Turnover Ratio Statistics
High	Average	Low
17.35	12.14	5.72
(Mar 31 2021)		(Sep 30 2022)

News about Mannkind Corporation Receivables Turnover Ratios

MannKind Corporation Advances in Pulmonary Fibrotic Disease Treatment and Shows Stronger Financial Health

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases MannKind Corporation has announced a significant milestone with the successful completion of a Phase 1 clinical trial for its innovative dry powder inhaler (DPI) formulation of nintedanib, targeted at treating pulmonary fibrotic diseases. This breakthrough in the company s product pipeline holds promise for patients suffering from conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, where current treatment options are limited.The Phase 1 trial was designed to assess the safety, tolerability, and pharmacokinetics of nintedanib DPI, and the results have shown positive outcomes, reinforcing MannKind s commitment to addressing unmet medical needs in the respiratory space. Nintedanib, a well-characterized tyrosine kinase inhibitor, has previously been approved in oral formulation for treating IPF, but this novel delivery method aims to enhance patient adherence and improve bioavailability.

MNKD Company Profile • Back to MNKD Efficiency Comparisons • Compare MNKD Receivables Turnover Ratio to its Competitors

Financial Statements
Mannkind's Accounts Receivable	$ 28 Millions	Visit MNKD's Balance sheet
Mannkind's Sales TTM	$ 361 Millions	Visit MNKD's Income Statement
Sources of MNKD's Revenues		Visit MNKD's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MNKD's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MNKD's Growth Rates	MNKD's Roa	MNKD's Inventory Turnover Ratio	MNKD's Dividend Comparisons
MNKD's Profitability Ratios	MNKD's Roi	MNKD's Asset Turnover Ratio	MNKD's Dividend Growth
MNKD's Valuation Ratios	MNKD's Roe	MNKD's Financial Strength Ratios	MNKD's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Longduoduo Co Ltd	35.04	$ 2.132 Millions	$ 0.061 Millions
Innovative Eyewear Inc	33.59	$ 2.981 Millions	$ 0.089 Millions
Electrocore Inc	32.90	$ 34.458 Millions	$ 1.047 Millions
U S Physical Therapy Inc	30.94	$ 795.488 Millions	$ 25.708 Millions
Innovage Holding Corp	30.93	$ 949.172 Millions	$ 30.688 Millions
Invo Fertility Inc	29.40	$ 7.219 Millions	$ 0.246 Millions
Lineage Cell Therapeutics Inc	28.42	$ 14.779 Millions	$ 0.520 Millions
Meiragtx Holdings Plc	28.01	$ 79.758 Millions	$ 2.848 Millions
Cv Sciences Inc	27.37	$ 11.925 Millions	$ 0.436 Millions
Wave Life Sciences Ltd	27.36	$ 88.173 Millions	$ 3.223 Millions
Safe Pro Group Inc	27.29	$ 1.642 Millions	$ 0.060 Millions
Atara Biotherapeutics Inc	27.03	$ 23.540 Millions	$ 0.871 Millions
Biorestorative Therapies Inc	25.41	$ 0.363 Millions	$ 0.014 Millions
Jaguar Health Inc	24.65	$ 29.569 Millions	$ 1.200 Millions
Kiniksa Pharmaceuticals International Plc	24.63	$ 754.045 Millions	$ 30.618 Millions
Polomar Health Services, Inc.	24.47	$ 1.649 Millions	$ 0.067 Millions
Agenus Inc	24.33	$ 123.866 Millions	$ 5.091 Millions
Igc Pharma Inc	23.44	$ 1.166 Millions	$ 0.050 Millions
Cytomx Therapeutics Inc	23.09	$ 35.542 Millions	$ 1.539 Millions
Siga Technologies Inc	22.41	$ 93.777 Millions	$ 4.186 Millions
Lipocine Inc	22.09	$ 2.002 Millions	$ 0.091 Millions
Ataibeckley Inc	21.56	$ 3.488 Millions	$ 0.162 Millions
Fonar Corporation	21.15	$ 105.338 Millions	$ 4.981 Millions
Neuraxis Inc	20.94	$ 4.282 Millions	$ 0.204 Millions
Vystar Corporation	20.58	$ 0.048 Millions	$ 0.002 Millions
Lifemd Inc	19.91	$ 177.869 Millions	$ 8.934 Millions
Longeveron Inc	19.07	$ 1.216 Millions	$ 0.064 Millions
Sonida Senior Living Inc	18.82	$ 411.850 Millions	$ 21.878 Millions
Voyager Therapeutics Inc	17.99	$ 36.494 Millions	$ 2.029 Millions
Nutriband Inc	16.79	$ 1.803 Millions	$ 0.107 Millions

Date modified: 2026-08-30T14:45:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.